172 related articles for article (PubMed ID: 37187725)
1. The Patient Journey from Randomization to Detection of Prostate Cancer and Death: Results from ERSPC Rotterdam.
Remmers S; Nieboer D; Roobol MJ;
Eur Urol Open Sci; 2023 May; 51():1-6. PubMed ID: 37187725
[TBL] [Abstract][Full Text] [Related]
2. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.
Roobol MJ; Kranse R; Bangma CH; van Leenders AG; Blijenberg BG; van Schaik RH; Kirkels WJ; Otto SJ; van der Kwast TH; de Koning HJ; Schröder FH;
Eur Urol; 2013 Oct; 64(4):530-9. PubMed ID: 23759326
[TBL] [Abstract][Full Text] [Related]
3. A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer.
de Vos II; Meertens A; Hogenhout R; Remmers S; Roobol MJ;
Eur Urol; 2023 Oct; 84(4):426-434. PubMed ID: 37029074
[TBL] [Abstract][Full Text] [Related]
4. From Screening to Mortality Reduction: An Overview of Empirical Data on the Patient Journey in European Randomized Study of Screening for Prostate Cancer Rotterdam After 21 Years of Follow-up and a Reflection on Quality of Life.
Hogenhout R; Remmers S; van Slooten-Midderigh ME; de Vos II; Roobol MJ;
Eur Urol Oncol; 2023 Sep; ():. PubMed ID: 37690917
[TBL] [Abstract][Full Text] [Related]
5. Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer.
Remmers S; Bangma CH; Godtman RA; Carlsson SV; Auvinen A; Tammela TLJ; Denis LJ; Nelen V; Villers A; Rebillard X; Kwiatkowski M; Recker F; Wyler S; Zappa M; Puliti D; Gorini G; Paez A; Lujan M; Nieboer D; Schröder FH; Roobol MJ
Eur Urol; 2023 Nov; 84(5):503-509. PubMed ID: 37088597
[TBL] [Abstract][Full Text] [Related]
6. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.
Buzzoni C; Auvinen A; Roobol MJ; Carlsson S; Moss SM; Puliti D; de Koning HJ; Bangma CH; Denis LJ; Kwiatkowski M; Lujan M; Nelen V; Paez A; Randazzo M; Rebillard X; Tammela TL; Villers A; Hugosson J; Schröder FH; Zappa M
Eur Urol; 2015 Nov; 68(5):885-90. PubMed ID: 25791513
[TBL] [Abstract][Full Text] [Related]
7. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH; Hugosson J; Carlsson S; Tammela T; Määttänen L; Auvinen A; Kwiatkowski M; Recker F; Roobol MJ
Eur Urol; 2012 Nov; 62(5):745-52. PubMed ID: 22704366
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
Bokhorst LP; Bangma CH; van Leenders GJ; Lous JJ; Moss SM; Schröder FH; Roobol MJ
Eur Urol; 2014 Feb; 65(2):329-36. PubMed ID: 23954085
[TBL] [Abstract][Full Text] [Related]
9. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam.
de Vos II; Remmers S; Hogenhout R; Roobol MJ;
Eur Urol; 2024 Jan; 85(1):74-81. PubMed ID: 37919190
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).
Roobol MJ; Kerkhof M; Schröder FH; Cuzick J; Sasieni P; Hakama M; Stenman UH; Ciatto S; Nelen V; Kwiatkowski M; Lujan M; Lilja H; Zappa M; Denis L; Recker F; Berenguer A; Ruutu M; Kujala P; Bangma CH; Aus G; Tammela TL; Villers A; Rebillard X; Moss SM; de Koning HJ; Hugosson J; Auvinen A
Eur Urol; 2009 Oct; 56(4):584-91. PubMed ID: 19660851
[TBL] [Abstract][Full Text] [Related]
11. Results of the spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Update after 21 years of follow-up.
Luján Galán M; Páez Borda Á; Llanes González L; Romero Cajigal I; Berenguer Sánchez A
Actas Urol Esp (Engl Ed); 2020; 44(6):430-436. PubMed ID: 32147352
[TBL] [Abstract][Full Text] [Related]
12. A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.
Roobol MJ; Zhu X; Schröder FH; van Leenders GJ; van Schaik RH; Bangma CH; Steyerberg EW
Eur Urol; 2013 Apr; 63(4):627-33. PubMed ID: 22841675
[TBL] [Abstract][Full Text] [Related]
13. Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC).
Villers A; Bessaoud F; Trétarre B; Grosclaude P; Malavaud B; Rebillard X; Iborra F; Daubisse L; Malavaud S; Roobol M; Heijnsdijk EA; de Koning HJ; Hugosson J; Rischmann P; Soulié M
Prog Urol; 2020 Apr; 30(5):252-260. PubMed ID: 32197936
[TBL] [Abstract][Full Text] [Related]
14. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
15. Incidence of prostate cancer after termination of screening in a population-based randomised screening trial.
Grenabo Bergdahl A; Holmberg E; Moss S; Hugosson J
Eur Urol; 2013 Nov; 64(5):703-9. PubMed ID: 23721957
[TBL] [Abstract][Full Text] [Related]
16. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
17. Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up.
Osses DF; Remmers S; Schröder FH; van der Kwast T; Roobol MJ
Eur Urol; 2019 Mar; 75(3):374-377. PubMed ID: 30420254
[TBL] [Abstract][Full Text] [Related]
18. Update of the results of the Spanish branch of the European Randomized Study on Screening for Prostate Cancer (ERSPC).
Luján M; Páez Á; Angulo JC; Andrés G; Gimbernat H; Redondo C; Torres GM; Berenguer A
Actas Urol Esp; 2015 Sep; 39(7):405-13. PubMed ID: 25777669
[TBL] [Abstract][Full Text] [Related]
19. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]